Short Interest in BriaCell Therapeutics Corp. (NASDAQ:BCTX) Declines By 12.6%

BriaCell Therapeutics Corp. (NASDAQ:BCTX) was the recipient of a significant decrease in short interest during the month of June. As of June 15th, there was short interest totalling 628,300 shares, a decrease of 12.6% from the May 31st total of 718,900 shares. Based on an average daily volume of 121,800 shares, the short-interest ratio is presently 5.2 days. Approximately 4.1% of the company’s shares are short sold.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and set a $18.00 price objective on shares of BriaCell Therapeutics in a research note on Tuesday, June 4th.

BriaCell Therapeutics Price Performance

BCTX traded up $0.10 during trading on Friday, hitting $1.14. 82,875 shares of the company’s stock were exchanged, compared to its average volume of 105,405. BriaCell Therapeutics has a 1 year low of $0.95 and a 1 year high of $7.59. The stock has a 50 day moving average price of $1.66 and a 200 day moving average price of $2.95.

BriaCell Therapeutics (NASDAQ:BCTX) last released its quarterly earnings data on Friday, June 14th. The company reported $0.11 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.66. On average, analysts expect that BriaCell Therapeutics will post -1.39 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. K.J. Harrison & Partners Inc boosted its stake in shares of BriaCell Therapeutics by 7.8% in the first quarter. K.J. Harrison & Partners Inc now owns 87,044 shares of the company’s stock valued at $249,000 after purchasing an additional 6,329 shares during the period. Onyx Bridge Wealth Group LLC boosted its stake in BriaCell Therapeutics by 66.7% during the 1st quarter. Onyx Bridge Wealth Group LLC now owns 50,000 shares of the company’s stock valued at $143,000 after acquiring an additional 20,000 shares during the last quarter. Finally, National Bank of Canada FI boosted its stake in BriaCell Therapeutics by 200.0% during the 4th quarter. National Bank of Canada FI now owns 7,500 shares of the company’s stock valued at $40,000 after acquiring an additional 5,000 shares during the last quarter. 15.42% of the stock is currently owned by hedge funds and other institutional investors.

About BriaCell Therapeutics

BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers.